# SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

> **NCT07417241** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** SHR-A1811
- **DRUG:** Pyrotinib
- **DRUG:** Capecitabine
- **DRUG:** T-DXd

## Key facts

- **NCT ID:** NCT07417241
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2029-01-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07417241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07417241, "SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study". Retrieved via AI Analytics 2026-07-22 from https://api.ai-analytics.org/clinical/NCT07417241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*